December saw shares of Rigel Pharmaceuticals (RIGL -0.67%) drop more than 20%. The tumble happened after Rigel's partner AstraZeneca (AZN -0.75%) released phase 2b data concerning their experimental rheumatoid arthritis drug fostamatinib. While the drug outperformed the placebo, it failed to beat AbbVie's (ABBV 0.97%) Humira. (AbbVie, formerly the branded pharmaceutical division of health care powerhouse Abbott Labs (ABT 0.16%), is now listed on the NYSE). In this video, Motley Fool health care analysts Max Macaluso and Brenton Flynn break down this story for investors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.